Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study

Abstract Context Programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), and T-cell immunoglobulin and ITIM domain (TIGIT) are considered major immune co-inhibitory receptors...

Full description

Saved in:
Bibliographic Details
Published inThe journal of clinical endocrinology and metabolism Vol. 106; no. 1; pp. 120 - 132
Main Authors Shi, Xiao, Li, Cui-Wei, Tan, Li-Cheng, Wen, Shi-Shuai, Liao, Tian, Zhang, Yan, Chen, Tong-Zhen, Ma, Ben, Yu, Peng-Cheng, Lu, Zhong-Wu, Qu, Ning, Wang, Yu, Shi, Rong-Liang, Wang, Yu-Long, Ji, Qing-Hai, Wei, Wen-Jun
Format Journal Article
LanguageEnglish
Published US Oxford University Press 01.01.2021
Copyright Oxford University Press
Subjects
Analysis
Antigens
Apoptosis
Cancer
Cancer therapies
Care and treatment
CD223 antigen
Cell activation
Cell death
CTLA-4 protein
Cytotoxicity
DNA microarrays
Health aspects
Immune response
Immunogenicity
Immunoglobulins
Immunohistochemistry
Immunotherapy
Lymphocytes T
Oncology, Experimental
Patients
PD-1 protein
PD-L1 protein
Proteins
Rankings
T cells
Thyroid cancer
Thyroid carcinoma
Thyroid gland
Vandetanib
China
PD-L1
immune co-inhibitory receptors
CTLA-4
medullary thyroid carcinoma
TIM-3
PD-1
Online AccessGet full text

Cover

Abstract Abstract Context Programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), and T-cell immunoglobulin and ITIM domain (TIGIT) are considered major immune co-inhibitory receptors (CIRs) and the most promising immunotherapeutic targets in cancer treatment, but they are largely unexplored in medullary thyroid carcinoma (MTC). Objective We aimed to provide the first evidence regarding the expression profiles and clinical significance of CIRs in a large cohort of MTC patients. Design and Patients In total, 200 MTC patients who received initial surgery in our hospital were included. Immunohistochemistry was performed to evaluate CIR expressions in tissue microarrays (TMAs). Combined with the results of our previous programmed cell death ligand-1 (PD-L1) study, clinicopathologic and prognostic correlations of these proteins were retrospectively analyzed. Results TIM-3, PD-1, CTLA-4, LAG-3, and TIGIT positivity was detected in 96 (48.0%), 27 (13.5%), 25 (12.5%), 6 (3.0%), and 6 (3.0%) patients, respectively, in whom TIM-3, PD-1, and CTLA-4 expressions were positively correlated. Log-rank tests and multivariate Cox analyses both indicated that TIM-3, CTLA-4 expression, and PD-1/PD-L1 coexpression were associated with worse structural recurrence-free survival. In addition, among 20 patients who developed advanced disease during follow-up, 12 (60%) showed TIM-3 positivity, among whom 6 cases also had concurrent moderate to strong PD-1, PD-L1, or CTLA-4 expression. Conclusions Using the currently largest TMA cohort of this rare cancer, we delineated the CIR expression profiles in MTC, and identified TIM-3, CTLA-4 expression, and PD-1/PD-L1 coexpression as promising biomarkers for tumor recurrence. Furthermore, a subset of advanced MTCs are probably immunogenic, for which single or combined immunotherapy including TIM-3, PD-1, PD-L1, or CTLA-4 blockade may be potential therapeutic approaches in the future.
AbstractList Context Programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), and T-cell immunoglobulin and ITIM domain (TIGIT) are considered major immune co-inhibitory receptors (CIRs) and the most promising immunotherapeutic targets in cancer treatment, but they are largely unexplored in medullary thyroid carcinoma (MTC). Objective We aimed to provide the first evidence regarding the expression profiles and clinical significance of CIRs in a large cohort of MTC patients. Design and Patients In total, 200 MTC patients who received initial surgery in our hospital were included. Immunohistochemistry was performed to evaluate CIR expressions in tissue microarrays (TMAs). Combined with the results of our previous programmed cell death ligand-1 (PD-L1) study, clinicopathologic and prognostic correlations of these proteins were retrospectively analyzed. Results TIM-3, PD-1, CTLA-4, LAG-3, and TIGIT positivity was detected in 96 (48.0%), 27 (13.5%), 25 (12.5%), 6 (3.0%), and 6 (3.0%) patients, respectively, in whom TIM-3, PD-1, and CTLA-4 expressions were positively correlated. Log-rank tests and multivariate Cox analyses both indicated that TIM-3, CTLA-4 expression, and PD-1/PD-L1 coexpression were associated with worse structural recurrence-free survival. In addition, among 20 patients who developed advanced disease during follow-up, 12 (60%) showed TIM-3 positivity, among whom 6 cases also had concurrent moderate to strong PD-1, PD-L1, or CTLA-4 expression. Conclusions Using the currently largest TMA cohort of this rare cancer, we delineated the CIR expression profiles in MTC, and identified TIM-3, CTLA-4 expression, and PD-1/PD-L1 coexpression as promising biomarkers for tumor recurrence. Furthermore, a subset of advanced MTCs are probably immunogenic, for which single or combined immunotherapy including TIM-3, PD-1, PD-L1, or CTLA-4 blockade may be potential therapeutic approaches in the future.
Freeform/Key Words: medullary thyroid carcinoma, immune co-inhibitory receptors, TIM-3, PD-1, PD-L1, CTLA-4
Abstract Context Programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), and T-cell immunoglobulin and ITIM domain (TIGIT) are considered major immune co-inhibitory receptors (CIRs) and the most promising immunotherapeutic targets in cancer treatment, but they are largely unexplored in medullary thyroid carcinoma (MTC). Objective We aimed to provide the first evidence regarding the expression profiles and clinical significance of CIRs in a large cohort of MTC patients. Design and Patients In total, 200 MTC patients who received initial surgery in our hospital were included. Immunohistochemistry was performed to evaluate CIR expressions in tissue microarrays (TMAs). Combined with the results of our previous programmed cell death ligand-1 (PD-L1) study, clinicopathologic and prognostic correlations of these proteins were retrospectively analyzed. Results TIM-3, PD-1, CTLA-4, LAG-3, and TIGIT positivity was detected in 96 (48.0%), 27 (13.5%), 25 (12.5%), 6 (3.0%), and 6 (3.0%) patients, respectively, in whom TIM-3, PD-1, and CTLA-4 expressions were positively correlated. Log-rank tests and multivariate Cox analyses both indicated that TIM-3, CTLA-4 expression, and PD-1/PD-L1 coexpression were associated with worse structural recurrence-free survival. In addition, among 20 patients who developed advanced disease during follow-up, 12 (60%) showed TIM-3 positivity, among whom 6 cases also had concurrent moderate to strong PD-1, PD-L1, or CTLA-4 expression. Conclusions Using the currently largest TMA cohort of this rare cancer, we delineated the CIR expression profiles in MTC, and identified TIM-3, CTLA-4 expression, and PD-1/PD-L1 coexpression as promising biomarkers for tumor recurrence. Furthermore, a subset of advanced MTCs are probably immunogenic, for which single or combined immunotherapy including TIM-3, PD-1, PD-L1, or CTLA-4 blockade may be potential therapeutic approaches in the future.
Programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), and T-cell immunoglobulin and ITIM domain (TIGIT) are considered major immune co-inhibitory receptors (CIRs) and the most promising immunotherapeutic targets in cancer treatment, but they are largely unexplored in medullary thyroid carcinoma (MTC).CONTEXTProgrammed cell death protein-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), and T-cell immunoglobulin and ITIM domain (TIGIT) are considered major immune co-inhibitory receptors (CIRs) and the most promising immunotherapeutic targets in cancer treatment, but they are largely unexplored in medullary thyroid carcinoma (MTC).We aimed to provide the first evidence regarding the expression profiles and clinical significance of CIRs in a large cohort of MTC patients.OBJECTIVEWe aimed to provide the first evidence regarding the expression profiles and clinical significance of CIRs in a large cohort of MTC patients.In total, 200 MTC patients who received initial surgery in our hospital were included. Immunohistochemistry was performed to evaluate CIR expressions in tissue microarrays (TMAs). Combined with the results of our previous programmed cell death ligand-1 (PD-L1) study, clinicopathologic and prognostic correlations of these proteins were retrospectively analyzed.DESIGN AND PATIENTSIn total, 200 MTC patients who received initial surgery in our hospital were included. Immunohistochemistry was performed to evaluate CIR expressions in tissue microarrays (TMAs). Combined with the results of our previous programmed cell death ligand-1 (PD-L1) study, clinicopathologic and prognostic correlations of these proteins were retrospectively analyzed.TIM-3, PD-1, CTLA-4, LAG-3, and TIGIT positivity was detected in 96 (48.0%), 27 (13.5%), 25 (12.5%), 6 (3.0%), and 6 (3.0%) patients, respectively, in whom TIM-3, PD-1, and CTLA-4 expressions were positively correlated. Log-rank tests and multivariate Cox analyses both indicated that TIM-3, CTLA-4 expression, and PD-1/PD-L1 coexpression were associated with worse structural recurrence-free survival. In addition, among 20 patients who developed advanced disease during follow-up, 12 (60%) showed TIM-3 positivity, among whom 6 cases also had concurrent moderate to strong PD-1, PD-L1, or CTLA-4 expression.RESULTSTIM-3, PD-1, CTLA-4, LAG-3, and TIGIT positivity was detected in 96 (48.0%), 27 (13.5%), 25 (12.5%), 6 (3.0%), and 6 (3.0%) patients, respectively, in whom TIM-3, PD-1, and CTLA-4 expressions were positively correlated. Log-rank tests and multivariate Cox analyses both indicated that TIM-3, CTLA-4 expression, and PD-1/PD-L1 coexpression were associated with worse structural recurrence-free survival. In addition, among 20 patients who developed advanced disease during follow-up, 12 (60%) showed TIM-3 positivity, among whom 6 cases also had concurrent moderate to strong PD-1, PD-L1, or CTLA-4 expression.Using the currently largest TMA cohort of this rare cancer, we delineated the CIR expression profiles in MTC, and identified TIM-3, CTLA-4 expression, and PD-1/PD-L1 coexpression as promising biomarkers for tumor recurrence. Furthermore, a subset of advanced MTCs are probably immunogenic, for which single or combined immunotherapy including TIM-3, PD-1, PD-L1, or CTLA-4 blockade may be potential therapeutic approaches in the future.CONCLUSIONSUsing the currently largest TMA cohort of this rare cancer, we delineated the CIR expression profiles in MTC, and identified TIM-3, CTLA-4 expression, and PD-1/PD-L1 coexpression as promising biomarkers for tumor recurrence. Furthermore, a subset of advanced MTCs are probably immunogenic, for which single or combined immunotherapy including TIM-3, PD-1, PD-L1, or CTLA-4 blockade may be potential therapeutic approaches in the future.
Context: Programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), and T-cell immunoglobulin and ITIM domain (TIGIT) are considered major immune co-inhibitory receptors (CIRs) and the most promising immunotherapeutic targets in cancer treatment, but they are largely unexplored in medullary thyroid carcinoma (MTC). Objective: We aimed to provide the first evidence regarding the expression profiles and clinical significance of CIRs in a large cohort of MTC patients. Design and Patients: In total, 200 MTC patients who received initial surgery in our hospital were included. Immunohistochemistry was performed to evaluate CIR expressions in tissue microarrays (TMAs). Combined with the results of our previous programmed cell death ligand-1 (PD-L1) study, clinicopathologic and prognostic correlations of these proteins were retrospectively analyzed. Results: TIM-3, PD-1, CTLA-4, LAG-3, and TIGIT positivity was detected in 96 (48.0%), 27 (13.5%), 25 (12.5%), 6 (3.0%), and 6 (3.0%) patients, respectively, in whom TIM-3, PD-1, and CTLA-4 expressions were positively correlated. Log-rank tests and multivariate Cox analyses both indicated that TIM-3, CTLA-4 expression, and PD-1/PD-L1 coexpression were associated with worse structural recurrence-free survival. In addition, among 20 patients who developed advanced disease during follow-up, 12 (60%) showed TIM-3 positivity, among whom 6 cases also had concurrent moderate to strong PD-1, PD-L1, or CTLA-4 expression. Conclusions: Using the currently largestTMA cohort of this rare cancer, we delineated the CIR expression profiles in MTC, and identified TIM-3, CTLA-4 expression, and PD-1/PD-L1 coexpression as promising biomarkers for tumor recurrence. Furthermore, a subset of advanced MTCs are probably immunogenic, for which single or combined immunotherapy including TIM-3, PD-1, PD-L1, or CTLA-4 blockade may be potential therapeutic approaches in the future. Freeform/Key Words: medullary thyroid carcinoma, immune co-inhibitory receptors, TIM-3, PD-1, PD-L1, CTLA-4
Programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), and T-cell immunoglobulin and ITIM domain (TIGIT) are considered major immune co-inhibitory receptors (CIRs) and the most promising immunotherapeutic targets in cancer treatment, but they are largely unexplored in medullary thyroid carcinoma (MTC). We aimed to provide the first evidence regarding the expression profiles and clinical significance of CIRs in a large cohort of MTC patients. In total, 200 MTC patients who received initial surgery in our hospital were included. Immunohistochemistry was performed to evaluate CIR expressions in tissue microarrays (TMAs). Combined with the results of our previous programmed cell death ligand-1 (PD-L1) study, clinicopathologic and prognostic correlations of these proteins were retrospectively analyzed. TIM-3, PD-1, CTLA-4, LAG-3, and TIGIT positivity was detected in 96 (48.0%), 27 (13.5%), 25 (12.5%), 6 (3.0%), and 6 (3.0%) patients, respectively, in whom TIM-3, PD-1, and CTLA-4 expressions were positively correlated. Log-rank tests and multivariate Cox analyses both indicated that TIM-3, CTLA-4 expression, and PD-1/PD-L1 coexpression were associated with worse structural recurrence-free survival. In addition, among 20 patients who developed advanced disease during follow-up, 12 (60%) showed TIM-3 positivity, among whom 6 cases also had concurrent moderate to strong PD-1, PD-L1, or CTLA-4 expression. Using the currently largest TMA cohort of this rare cancer, we delineated the CIR expression profiles in MTC, and identified TIM-3, CTLA-4 expression, and PD-1/PD-L1 coexpression as promising biomarkers for tumor recurrence. Furthermore, a subset of advanced MTCs are probably immunogenic, for which single or combined immunotherapy including TIM-3, PD-1, PD-L1, or CTLA-4 blockade may be potential therapeutic approaches in the future.
Audience Academic
Author Ma, Ben
Wang, Yu
Liao, Tian
Li, Cui-Wei
Lu, Zhong-Wu
Tan, Li-Cheng
Wen, Shi-Shuai
Wang, Yu-Long
Yu, Peng-Cheng
Shi, Rong-Liang
Chen, Tong-Zhen
Qu, Ning
Wei, Wen-Jun
Zhang, Yan
Shi, Xiao
Ji, Qing-Hai
AuthorAffiliation Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
AuthorAffiliation_xml – name: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Author_xml – sequence: 1
  givenname: Xiao
  surname: Shi
  fullname: Shi, Xiao
  email: shirongliang@126.com
  organization: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
– sequence: 2
  givenname: Cui-Wei
  surname: Li
  fullname: Li, Cui-Wei
  email: shirongliang@126.com
  organization: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
– sequence: 3
  givenname: Li-Cheng
  surname: Tan
  fullname: Tan, Li-Cheng
  organization: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
– sequence: 4
  givenname: Shi-Shuai
  surname: Wen
  fullname: Wen, Shi-Shuai
  email: kakarwen@163.com
  organization: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
– sequence: 5
  givenname: Tian
  surname: Liao
  fullname: Liao, Tian
  organization: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
– sequence: 6
  givenname: Yan
  surname: Zhang
  fullname: Zhang, Yan
  organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
– sequence: 7
  givenname: Tong-Zhen
  surname: Chen
  fullname: Chen, Tong-Zhen
  organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
– sequence: 8
  givenname: Ben
  surname: Ma
  fullname: Ma, Ben
  organization: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
– sequence: 9
  givenname: Peng-Cheng
  surname: Yu
  fullname: Yu, Peng-Cheng
  organization: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
– sequence: 10
  givenname: Zhong-Wu
  surname: Lu
  fullname: Lu, Zhong-Wu
  organization: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
– sequence: 11
  givenname: Ning
  surname: Qu
  fullname: Qu, Ning
  organization: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
– sequence: 12
  givenname: Yu
  surname: Wang
  fullname: Wang, Yu
  organization: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
– sequence: 13
  givenname: Rong-Liang
  surname: Shi
  fullname: Shi, Rong-Liang
  email: shirongliang@126.com
  organization: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
– sequence: 14
  givenname: Yu-Long
  surname: Wang
  fullname: Wang, Yu-Long
  email: wylheadneck@sina.com
  organization: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
– sequence: 15
  givenname: Qing-Hai
  orcidid: 0000-0003-1006-8503
  surname: Ji
  fullname: Ji, Qing-Hai
  email: jq_hai@126.com
  organization: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
– sequence: 16
  givenname: Wen-Jun
  surname: Wei
  fullname: Wei, Wen-Jun
  email: kakarwen@163.com
  organization: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33000173$$D View this record in MEDLINE/PubMed
BookMark eNqFkl1v0zAUhi00xLrBLZfIEjcgNZu_GifcRQFKpU4g1gvuLNd2G4_ELnaiqv8eRy1MTAxkyR9H73POK59zAc6cdwaAlxhdYYLRtWqtM9213krJEX4CJrhks4zjkp-BCUIEZyUn387BRYx3CGHGZvQZOKcUpQenE7BfdN3gDKx9Zl1j17b34QC_GmV26Rbhl_cZnsJ6tawyNoWrxU1Gp3BZzcdDOp0i88UKWgdvjB7aViZ41RyCtxrW0ikT4jtYwaUM27FG40MPb_tBH56DpxvZRvPidF6C248fVvWnbPl5vqirZaZmOcaZIUohneO11rNiVpZY05xQrdFGcl2mqCZpKwuypiVVzPCCK1oglGPOJKWX4M0x6y74H4OJvehsVCb5dMYPURDGeEELmrMkff1AeueH4JI3QTFHiOMk-5eKlMkxRZige9VWtkZYt_F9kGosLSqOCGGE5aO5q7-o0tKmsyq1eWNT_A_g1an4sO6MFrtgu_Th4lc37zOq4GMMZvNbgpEYx0Ucx0WcxiUB7AGgbC97612yYtvHMXLE9r7tU4u_t8PeBNEY2fbN49DbI-SH3f98_QTOIN8K
CitedBy_id crossref_primary_10_1016_j_heliyon_2023_e22656
crossref_primary_10_3389_fendo_2024_1418657
crossref_primary_10_3389_fcvm_2024_1232269
crossref_primary_10_3390_cancers16213632
crossref_primary_10_3389_fonc_2022_1018479
crossref_primary_10_1080_1744666X_2024_2328746
crossref_primary_10_1186_s12935_023_03157_5
crossref_primary_10_3389_fimmu_2022_982026
crossref_primary_10_2217_fon_2023_0658
crossref_primary_10_1155_2021_5440572
crossref_primary_10_1186_s13048_023_01179_1
crossref_primary_10_3389_fendo_2022_929091
crossref_primary_10_3390_ph15121565
crossref_primary_10_3390_vaccines12010045
crossref_primary_10_1093_oncolo_oyad165
crossref_primary_10_3389_fendo_2022_864253
crossref_primary_10_3389_fimmu_2023_1308264
crossref_primary_10_3390_cancers16132296
crossref_primary_10_1093_cei_uxae026
crossref_primary_10_3390_cancers14153643
crossref_primary_10_3390_jpm13071132
crossref_primary_10_1155_2022_4983532
crossref_primary_10_3390_cancers14081951
crossref_primary_10_1016_j_coemr_2024_100544
crossref_primary_10_1002_iub_2558
crossref_primary_10_1007_s11864_023_01145_5
crossref_primary_10_1038_s41416_024_02877_3
crossref_primary_10_1007_s12094_024_03836_3
crossref_primary_10_1038_s41421_022_00479_y
crossref_primary_10_1097_MED_0000000000000662
crossref_primary_10_3389_fimmu_2023_1219487
crossref_primary_10_1530_EJE_22_0312
crossref_primary_10_3389_fimmu_2024_1302587
crossref_primary_10_1055_a_1908_7790
crossref_primary_10_3389_fendo_2024_1484815
crossref_primary_10_1186_s12902_022_01113_4
crossref_primary_10_3389_fimmu_2022_1055412
crossref_primary_10_3923_ajbs_2025_179_194
crossref_primary_10_1016_j_prp_2024_155468
crossref_primary_10_1007_s40618_023_02126_z
crossref_primary_10_1097_CCO_0000000000000915
crossref_primary_10_3389_fimmu_2023_1121285
crossref_primary_10_3389_fendo_2021_667784
crossref_primary_10_31083_j_fbl2905202
crossref_primary_10_3390_life13041050
crossref_primary_10_3390_jcm13237161
crossref_primary_10_1080_08820139_2023_2268656
crossref_primary_10_1371_journal_pone_0297695
crossref_primary_10_3390_cancers14133194
crossref_primary_10_2174_0113894501269090231012090351
crossref_primary_10_1111_ajco_13836
Cites_doi 10.1200/JCO.2017.35.15_suppl.e14589
10.1016/j.cell.2018.09.035
10.1126/science.271.5256.1734
10.1136/jitc-2020-000552
10.1073/pnas.1722043115
10.1002/hep.29360
10.1245/s10434-010-1339-y
10.1056/NEJMoa1504030
10.1158/0008-5472.CAN-19-2834
10.1002/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0
10.1186/1479-5876-11-108
10.1080/2162402X.2017.1408747
10.1093/annonc/mdx479
10.1089/thy.2019.0604
10.1038/s41590-019-0512-0
10.2147/OTT.S237222
10.1200/JCO.2011.35.5040
10.1080/13543776.2019.1637422
10.1158/2159-8290.CD-18-0338
10.1016/j.immuni.2016.05.001
10.1093/annonc/mdy547
10.1038/s41379-019-0433-3
10.1084/jem.20100643
10.1038/s41388-018-0140-4
10.1172/JCI59806
10.1016/j.ccell.2018.03.005
10.18632/oncotarget.15954
10.1002/hed.25463
10.1073/pnas.1100551108
10.1038/nm.2871
10.1073/pnas.1921445117
10.1093/annonc/mdy137
10.1172/JCI80011
10.1016/j.ejso.2018.10.060
10.3389/fimmu.2018.02821
10.1530/ERC-17-0104
10.1007/s12022-013-9287-2
10.1089/thy.2019.0079
10.1186/s12943-019-1091-2
10.1016/j.cell.2015.08.052
10.1084/jem.20090397
ContentType Journal Article
Copyright The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2020
Copyright © Oxford University Press 2015
The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
COPYRIGHT 2021 Oxford University Press
The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
Copyright_xml – notice: The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2020
– notice: Copyright © Oxford University Press 2015
– notice: The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
– notice: COPYRIGHT 2021 Oxford University Press
– notice: The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
DBID AAYXX
CITATION
NPM
7QP
7T5
7TM
H94
K9.
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1210/clinem/dgaa701
DatabaseName CrossRef
PubMed
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Calcium & Calcified Tissue Abstracts
Nucleic Acids Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList AIDS and Cancer Research Abstracts


MEDLINE - Academic
ProQuest One Academic Middle East (New)

PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1945-7197
EndPage 132
ExternalDocumentID A702242463
33000173
10_1210_clinem_dgaa701
10.1210/clinem/dgaa701
Genre Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GroupedDBID ---
-~X
.55
.GJ
.XZ
08P
0R~
18M
1TH
29K
2WC
34G
354
39C
3O-
3V.
4.4
48X
53G
5GY
5RS
5YH
7X7
88E
8F7
8FI
8FJ
AABZA
AACZT
AAIMJ
AAJQQ
AAKAS
AAPGJ
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
AAYJJ
ABBLC
ABDFA
ABDPE
ABEJV
ABGNP
ABJNI
ABLJU
ABMNT
ABNHQ
ABOCM
ABPMR
ABPPZ
ABPQP
ABPTD
ABQNK
ABUWG
ABVGC
ABWST
ABXVV
ACFRR
ACGFO
ACGFS
ACPRK
ACUTJ
ACYHN
ACZBC
ADBBV
ADGKP
ADGZP
ADHKW
ADQBN
ADRTK
ADVEK
ADZCM
AELWJ
AEMDU
AENEX
AENZO
AERZD
AETBJ
AEWNT
AFCHL
AFFNX
AFFQV
AFFZL
AFGWE
AFKRA
AFOFC
AFRAH
AFXAL
AFYAG
AGINJ
AGKRT
AGMDO
AGQXC
AGUTN
AHMBA
AHMMS
AI.
AJEEA
ALMA_UNASSIGNED_HOLDINGS
APIBT
APJGH
AQDSO
AQKUS
ARIXL
ASPBG
ATGXG
AVWKF
AZFZN
BAWUL
BAYMD
BCRHZ
BENPR
BEYMZ
BPHCQ
BSWAC
BTRTY
BVXVI
C45
CCPQU
CDBKE
CS3
D-I
DAKXR
DIK
E3Z
EBS
EIHJH
EJD
EMOBN
ENERS
F5P
FECEO
FEDTE
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
FYUFA
GAUVT
GJXCC
GX1
H13
HMCUK
HVGLF
HZ~
H~9
IAO
IHR
INH
ITC
J5H
KBUDW
KOP
KQ8
KSI
KSN
L7B
M1P
M5~
MBLQV
MHKGH
MJL
N4W
N9A
NLBLG
NOMLY
NOYVH
NVLIB
O9-
OAUYM
OBH
OCB
ODMLO
OFXIZ
OGEVE
OHH
OJZSN
OK1
OPAEJ
OVD
OVIDX
P2P
P6G
PQQKQ
PROAC
PSQYO
REU
ROX
ROZ
TEORI
TJX
TLC
TMA
TR2
TWZ
UKHRP
VH1
VVN
W8F
WHG
WOQ
X52
X7M
YBU
YFH
YHG
YOC
YSK
ZGI
ZXP
ZY1
~02
~H1
ABXZS
ADNBA
AEMQT
AEOTA
AGORE
AHGBF
AJBYB
ALXQX
NU-
PHGZM
PHGZT
AAYXX
CITATION
NPM
PMFND
7QP
7T5
7TM
H94
K9.
PJZUB
PPXIY
7XB
8FK
PKEHL
PQEST
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c5611-e2cc0d61bdd585991d3623dd0fa7d9bddd2bdd982b393c4e787c38006174a33
IEDL.DBID 7X7
ISSN 0021-972X
1945-7197
IngestDate Tue Aug 05 11:01:47 EDT 2025
Fri Jul 25 21:32:43 EDT 2025
Fri Jul 25 20:48:02 EDT 2025
Tue Jun 17 21:21:37 EDT 2025
Tue Jun 10 20:15:05 EDT 2025
Wed Feb 19 02:29:17 EST 2025
Thu Apr 24 23:05:48 EDT 2025
Tue Jul 01 01:10:59 EDT 2025
Fri May 16 03:49:05 EDT 2025
Fri Feb 07 10:35:35 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords PD-L1
immune co-inhibitory receptors
CTLA-4
medullary thyroid carcinoma
TIM-3
PD-1
Language English
License This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model
The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5611-e2cc0d61bdd585991d3623dd0fa7d9bddd2bdd982b393c4e787c38006174a33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-1006-8503
PMID 33000173
PQID 3170071836
PQPubID 2046206
PageCount 13
ParticipantIDs proquest_miscellaneous_2447838364
proquest_journals_3170071836
proquest_journals_2956130120
gale_infotracmisc_A702242463
gale_infotracacademiconefile_A702242463
pubmed_primary_33000173
crossref_primary_10_1210_clinem_dgaa701
crossref_citationtrail_10_1210_clinem_dgaa701
wolterskluwer_health_10_1210_clinem_dgaa701
oup_primary_10_1210_clinem_dgaa701
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-01-01
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-01
  day: 01
PublicationDecade 2020
PublicationPlace US
PublicationPlace_xml – name: US
– name: United States
– name: Washington
PublicationTitle The journal of clinical endocrinology and metabolism
PublicationTitleAlternate J Clin Endocrinol Metab
PublicationYear 2021
Publisher Oxford University Press
Copyright Oxford University Press
Publisher_xml – name: Oxford University Press
– name: Copyright Oxford University Press
References Du (2021122204030330900_CIT0035) 2018; 7
Shi (2021122204030330900_CIT0011)
Wu (2021122204030330900_CIT0029) 2010; 24
Shi (2021122204030330900_CIT0010) 2019; 29
Zhou (2021122204030330900_CIT0017) 2018; 9
Zhang (2021122204030330900_CIT0015) 2018; 37
Sanmamed (2021122204030330900_CIT0033) 2018; 175
Wells (2021122204030330900_CIT0004) 2012; 30
Luen (2021122204030330900_CIT0012) 2019; 30
Kulangara (2021122204030330900_CIT0018) 2017; 35
Huang (2021122204030330900_CIT0025) 2010; 207
Zhang (2021122204030330900_CIT0028) 2017; 8
Li (2021122204030330900_CIT0034) 2017; 66
Sakuishi (2021122204030330900_CIT0041) 2010; 207
Xiao (2021122204030330900_CIT0030) 2020; 13
Chen (2021122204030330900_CIT0031) 2018; 115
Leach (2021122204030330900_CIT0036) 1996; 271
Gilliland (2021122204030330900_CIT0002) 1997; 79
Subbiah (2021122204030330900_CIT0006) 2018; 29
Chen (2021122204030330900_CIT0032) 2015; 125
Rangachari (2021122204030330900_CIT0040) 2012; 18
Herrera-Camacho (2021122204030330900_CIT0043) 2019; 29
Anderson (2021122204030330900_CIT0008) 2016; 44
Wang (2021122204030330900_CIT0023) 2020; 117
Bi (2021122204030330900_CIT0019) 2019; 45
Pozdeyev (2021122204030330900_CIT0027) 2020; 30
Abraham (2021122204030330900_CIT0038) 2011; 18
Curley (2021122204030330900_CIT0020) 2020; 33
Jan (2021122204030330900_CIT0024) 2011; 108
Zappasodi (2021122204030330900_CIT0021) 2018; 33
Laurent (2021122204030330900_CIT0014) 2013; 11
Andrews (2021122204030330900_CIT0022) 2019; 20
Matias-Guiu (2021122204030330900_CIT0001) 2014; 25
Kleffel (2021122204030330900_CIT0013) 2015; 162
Klümper (2021122204030330900_CIT0016) 2020; 8
Schlumberger (2021122204030330900_CIT0003) 2017; 28
Yang (2021122204030330900_CIT0042) 2012; 122
Larkin (2021122204030330900_CIT0044) 2015; 373
Subbiah (2021122204030330900_CIT0005) 2018; 8
Qin (2021122204030330900_CIT0009) 2019; 18
Bongiovanni (2021122204030330900_CIT0039) 2017; 24
Kim (2021122204030330900_CIT0026) 2020; 80
Saltiki (2021122204030330900_CIT0037) 2019; 41
Lucca (2021122204030330900_CIT0007)
References_xml – volume: 35
  start-page: e14589
  issue: 15 Suppl
  year: 2017
  ident: 2021122204030330900_CIT0018
  article-title: Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.35.15_suppl.e14589
– volume: 175
  start-page: 313
  issue: 2
  year: 2018
  ident: 2021122204030330900_CIT0033
  article-title: A paradigm shift in cancer immunotherapy: from enhancement to normalization
  publication-title: Cell.
  doi: 10.1016/j.cell.2018.09.035
– volume: 271
  start-page: 1734
  issue: 5256
  year: 1996
  ident: 2021122204030330900_CIT0036
  article-title: Enhancement of antitumor immunity by CTLA-4 blockade
  publication-title: Science.
  doi: 10.1126/science.271.5256.1734
– volume: 8
  start-page: e000552
  issue: 1
  year: 2020
  ident: 2021122204030330900_CIT0016
  article-title: LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
  publication-title: J Immunother Cancer.
  doi: 10.1136/jitc-2020-000552
– volume: 115
  start-page: 3126
  issue: 12
  year: 2018
  ident: 2021122204030330900_CIT0031
  article-title: B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction
  publication-title: Proc Natl Acad Sci U S A.
  doi: 10.1073/pnas.1722043115
– volume: 66
  start-page: 1920
  issue: 6
  year: 2017
  ident: 2021122204030330900_CIT0034
  article-title: Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1
  publication-title: Hepatology.
  doi: 10.1002/hep.29360
– volume: 18
  start-page: 219
  issue: 1
  year: 2011
  ident: 2021122204030330900_CIT0038
  article-title: Medullary thyroid carcinoma: long-term outcomes of surgical treatment
  publication-title: Ann Surg Oncol.
  doi: 10.1245/s10434-010-1339-y
– volume: 373
  start-page: 23
  issue: 1
  year: 2015
  ident: 2021122204030330900_CIT0044
  article-title: Combined nivolumab anipilimumab or monotherapy in untreated melanoma
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1504030
– volume: 80
  start-page: 1833
  issue: 9
  year: 2020
  ident: 2021122204030330900_CIT0026
  article-title: Glial TIM-3 modulates immune responses in the brain tumor microenvironment
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-19-2834
– volume: 79
  start-page: 564
  issue: 3
  year: 1997
  ident: 2021122204030330900_CIT0002
  article-title: Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991
  publication-title: Cancer.
  doi: 10.1002/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0
– volume: 11
  start-page: 108
  year: 2013
  ident: 2021122204030330900_CIT0014
  article-title: The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production
  publication-title: J Transl Med.
  doi: 10.1186/1479-5876-11-108
– volume: 7
  start-page: e1408747
  issue: 4
  year: 2018
  ident: 2021122204030330900_CIT0035
  article-title: Blockade of tumor-expressed PD-1 promotes lung cancer growth
  publication-title: Oncoimmunology.
  doi: 10.1080/2162402X.2017.1408747
– volume: 28
  start-page: 2813
  issue: 11
  year: 2017
  ident: 2021122204030330900_CIT0003
  article-title: Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma
  publication-title: Ann Oncol.
  doi: 10.1093/annonc/mdx479
– ident: 2021122204030330900_CIT0007
  article-title: Modulation of regulatory T cell function and stability by co-inhibitory receptors. [Published online ahead of print April 1, 2020.]
  publication-title: Nat Rev Immunol
– volume: 30
  start-page: 1263
  issue: 9
  year: 2020
  ident: 2021122204030330900_CIT0027
  article-title: Comprehensive immune profiling of medullary thyroid cancer
  publication-title: Thyroid.
  doi: 10.1089/thy.2019.0604
– volume: 20
  start-page: 1425
  issue: 11
  year: 2019
  ident: 2021122204030330900_CIT0022
  article-title: Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
  publication-title: Nat Immunol.
  doi: 10.1038/s41590-019-0512-0
– volume: 13
  start-page: 1993
  year: 2020
  ident: 2021122204030330900_CIT0030
  article-title: TIM-3 participates in the invasion and metastasis of nasopharyngeal carcinoma via SMAD7/SMAD2/SNAIL1 axis-mediated epithelial-mesenchymal transition
  publication-title: Onco Targets Ther.
  doi: 10.2147/OTT.S237222
– volume: 30
  start-page: 134
  issue: 2
  year: 2012
  ident: 2021122204030330900_CIT0004
  article-title: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2011.35.5040
– volume: 29
  start-page: 587
  issue: 8
  year: 2019
  ident: 2021122204030330900_CIT0043
  article-title: Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1
  publication-title: Expert Opin Ther Pat.
  doi: 10.1080/13543776.2019.1637422
– volume: 8
  start-page: 836
  issue: 7
  year: 2018
  ident: 2021122204030330900_CIT0005
  article-title: Precision targeted therapy with BLU-667 for RET-driven cancers
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-0338
– volume: 44
  start-page: 989
  issue: 5
  year: 2016
  ident: 2021122204030330900_CIT0008
  article-title: Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
  publication-title: Immunity.
  doi: 10.1016/j.immuni.2016.05.001
– ident: 2021122204030330900_CIT0011
– volume: 30
  start-page: 236
  issue: 2
  year: 2019
  ident: 2021122204030330900_CIT0012
  article-title: Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
  publication-title: Ann Oncol.
  doi: 10.1093/annonc/mdy547
– volume: 33
  start-page: 1182
  issue: 6
  year: 2020
  ident: 2021122204030330900_CIT0020
  article-title: Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia
  publication-title: Mod Pathol.
  doi: 10.1038/s41379-019-0433-3
– volume: 207
  start-page: 2187
  issue: 10
  year: 2010
  ident: 2021122204030330900_CIT0041
  article-title: Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
  publication-title: J Exp Med.
  doi: 10.1084/jem.20100643
– volume: 37
  start-page: 2456
  issue: 18
  year: 2018
  ident: 2021122204030330900_CIT0015
  article-title: Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis
  publication-title: Oncogene.
  doi: 10.1038/s41388-018-0140-4
– volume: 122
  start-page: 1271
  issue: 4
  year: 2012
  ident: 2021122204030330900_CIT0042
  article-title: IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma
  publication-title: J Clin Invest.
  doi: 10.1172/JCI59806
– volume: 24
  start-page: 693
  issue: 3
  year: 2010
  ident: 2021122204030330900_CIT0029
  article-title: Endothelial cell-expressed Tim-3 facilitates metastasis of melanoma cells by activating the NF-κB pathway
  publication-title: Oncol Rep.
– volume: 33
  start-page: 581
  issue: 4
  year: 2018
  ident: 2021122204030330900_CIT0021
  article-title: Emerging concepts for immune checkpoint blockade-based combination therapies
  publication-title: Cancer Cell.
  doi: 10.1016/j.ccell.2018.03.005
– volume: 8
  start-page: 31705
  issue: 19
  year: 2017
  ident: 2021122204030330900_CIT0028
  article-title: TIM-3 is a potential prognostic marker for patients with solid tumors: a systematic review and meta-analysis
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.15954
– volume: 41
  start-page: 154
  issue: 1
  year: 2019
  ident: 2021122204030330900_CIT0037
  article-title: Different outcomes in sporadic versus familial medullary thyroid cancer
  publication-title: Head Neck.
  doi: 10.1002/hed.25463
– volume: 108
  start-page: 5009
  issue: 12
  year: 2011
  ident: 2021122204030330900_CIT0024
  article-title: Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker
  publication-title: Proc Natl Acad Sci U S A.
  doi: 10.1073/pnas.1100551108
– volume: 18
  start-page: 1394
  issue: 9
  year: 2012
  ident: 2021122204030330900_CIT0040
  article-title: Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion
  publication-title: Nat Med.
  doi: 10.1038/nm.2871
– volume: 117
  start-page: 6640
  issue: 12
  year: 2020
  ident: 2021122204030330900_CIT0023
  article-title: Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy
  publication-title: Proc Natl Acad Sci U S A.
  doi: 10.1073/pnas.1921445117
– volume: 29
  start-page: 1869
  issue: 8
  year: 2018
  ident: 2021122204030330900_CIT0006
  article-title: Selective RET kinase inhibition for patients with RET-altered cancers
  publication-title: Ann Oncol.
  doi: 10.1093/annonc/mdy137
– volume: 125
  start-page: 3384
  issue: 9
  year: 2015
  ident: 2021122204030330900_CIT0032
  article-title: Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
  publication-title: J Clin Invest.
  doi: 10.1172/JCI80011
– volume: 45
  start-page: 353
  issue: 3
  year: 2019
  ident: 2021122204030330900_CIT0019
  article-title: PD-1/PD-L1 expressions in medullary thyroid carcinoma: clinicopathologic and prognostic analysis of Chinese population
  publication-title: Eur J Surg Oncol.
  doi: 10.1016/j.ejso.2018.10.060
– volume: 9
  start-page: 2821
  year: 2018
  ident: 2021122204030330900_CIT0017
  article-title: Intrinsic expression of immune checkpoint molecule TIGIT could help tumor growth in vivo by suppressing the function of NK and CD8+ T cells
  publication-title: Front Immunol.
  doi: 10.3389/fimmu.2018.02821
– volume: 24
  start-page: L35
  issue: 6
  year: 2017
  ident: 2021122204030330900_CIT0039
  article-title: Very low expression of PD-L1 in medullary thyroid carcinoma
  publication-title: Endocr Relat Cancer.
  doi: 10.1530/ERC-17-0104
– volume: 25
  start-page: 21
  issue: 1
  year: 2014
  ident: 2021122204030330900_CIT0001
  article-title: Medullary thyroid carcinoma: a 25-year perspective
  publication-title: Endocr Pathol.
  doi: 10.1007/s12022-013-9287-2
– volume: 29
  start-page: 1269
  issue: 9
  year: 2019
  ident: 2021122204030330900_CIT0010
  article-title: Association between programmed death-ligand 1 expression and clinicopathological characteristics, structural recurrence, and biochemical recurrence/persistent disease in medullary thyroid carcinoma
  publication-title: Thyroid.
  doi: 10.1089/thy.2019.0079
– volume: 18
  start-page: 155
  issue: 1
  year: 2019
  ident: 2021122204030330900_CIT0009
  article-title: Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
  publication-title: Mol Cancer.
  doi: 10.1186/s12943-019-1091-2
– volume: 162
  start-page: 1242
  issue: 6
  year: 2015
  ident: 2021122204030330900_CIT0013
  article-title: Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth
  publication-title: Cell.
  doi: 10.1016/j.cell.2015.08.052
– volume: 207
  start-page: 505
  issue: 3
  year: 2010
  ident: 2021122204030330900_CIT0025
  article-title: Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion
  publication-title: J Exp Med.
  doi: 10.1084/jem.20090397
SSID ssj0014453
Score 2.5548708
Snippet Abstract Context Programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3...
Programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte...
Context: Programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3),...
Freeform/Key Words: medullary thyroid carcinoma, immune co-inhibitory receptors, TIM-3, PD-1, PD-L1, CTLA-4
Context Programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3),...
SourceID proquest
gale
pubmed
crossref
wolterskluwer
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 120
SubjectTerms Analysis
Antigens
Apoptosis
Cancer
Cancer therapies
Care and treatment
CD223 antigen
Cell activation
Cell death
CTLA-4 protein
Cytotoxicity
DNA microarrays
Health aspects
Immune response
Immunogenicity
Immunoglobulins
Immunohistochemistry
Immunotherapy
Lymphocytes T
Oncology, Experimental
Patients
PD-1 protein
PD-L1 protein
Proteins
Rankings
T cells
Thyroid cancer
Thyroid carcinoma
Thyroid gland
Vandetanib
Title Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study
URI https://www.ncbi.nlm.nih.gov/pubmed/33000173
https://www.proquest.com/docview/2956130120
https://www.proquest.com/docview/3170071836
https://www.proquest.com/docview/2447838364
Volume 106
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3rb9MwED_BJiEQQrwXKJNBSHyg1trYzYMvKJQ9itppgiD1m-XYHo2GktJumvbfc5e4ZZUYfEml2LFPvTv7d_Y9AN6eGpfapIh4gRYQl7gh89RKxy3KT1zESRFKineeHEdH3-WX6WDqD9yW3q1ytSY2C7WtDZ2R7wlKJIcLqYg-zn9xqhpFt6u-hMZt2KbUZeTSFU_XBhfaCj4LJbkhxOHUJ22kqBWKO3Q4-g-tY18QZrUp-aV5I97tGuy8B_cva7rJXp41juzXtqODh_DA40iWtYx_BLdc9RjuTPxN-RO4HFHgh2PDmpfVrCxKukxnCBLdnOrrsJPPvN9lw3yccdll-WjCRZeNs0P60ZXFN4ejnJUVwyHRStX4cT67WtSlZUMSlMXyA8vYmPzIcY4ZgnhGLolXT-HbwX4-POK-yAI3CJ363IXG9GzUL6xFywHRosUtTVjbO9WxTfGtDfGRJmEhUmGkQwU3ImmQj9RCPIOtqq7cDjCJQDCJKBuN1chynRo9cCmiYmndYFDYAPjqP1bG5x-nMhg_FdkhyBPV8kR5ngTwbt1_3mbeuLknsUyRSuKIRvvIAqSLklupLCagEspIBNDZ6ImqZDaa3yDT_ztbZyUTyuv7UoVpY4j1w95fm_8IbwCv1800O7m4Va6-wCGkjBOBXWQAz1tRW1MiRJPYCAl8vyF7qg2WvYHSF_8m5SXcDUkzmvOkDmydLy7cK0RY58Vuo0a7sP1p__jk628ipSJ9
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1rixMxcDjuwAcivq1WjaL4wQbbJN2HIFJ7j9Zry3Gu0E8uu0nOFmW3tneU_id_pDO72XoFTz_dlxY2aTLdmcwj8wJ4eaJtaILU4ylaQFyhQOahUZYbpB8_9YNUKMp3Ho683hf1adweb8GvKheGwiornlgwapNruiN_K6mQHDJS6X2Y_eTUNYq8q1ULjZIsDu1qiSbb4n1_F_H7Soj9vajb466rANeoK7S4FVo3jddKjUFVGdUjgzxcGtM8SXwT4lMj8CMMRCpDqZVFitYyKES9Suj6Exn-jpJoyGzDzse90dHx2muhlKt6SWEPvhi7IpGUJUN5jhb_zbck8V0DmkoIOlGwkV93Ts29DjeWOXnOF9-LwPlz4m__Ftx0eivrlIR2G7ZsdgeuDJ1n_i4s-5RoYlk359NsMk2n5LxnqJTaGfXzYUe7vNVg3WjQ4arBov6QywYbdA7oK8kMPjnoR2yaMVwSreIEfxxNVvN8aliXCHO-eMc6bEBx67jHBI0GRiGQq3vw-RJe_33YzvLMPgSmUPEMPKp-YxIksSTUSduGqIUrY9vt1NSAV-841q7eObXd-BGT3YM4iUucxA4nNXi9nj8rK31cPJNQFhMLwBV14jIZEC4qphV3fFKMhPJkDeobM_Ho6o3hF4j0_-5Wr2gidvxlEYuwMPxaovnX4T-HpQbP18O0O4XUZTY_wyWU8gOJU1QNHpSktoZEyqKQEgL4ZoP24jI59wJIH_0blGdwtRcNB_GgPzp8DNcEnZLiLqsO26fzM_sEtbvT9Kk7VAy-Xu4p_g2VBl30
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immune+Co-inhibitory+Receptors+PD-1%2C+CTLA-4%2C+TIM-3%2C+LAG-3%2C+and+TIGIT+in+Medullary+Thyroid+Cancers%3A+A+Large+Cohort+Study&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Shi%2C+Xiao&rft.au=Li%2C+Cui-Wei&rft.au=Tan%2C+Li-Cheng&rft.au=Wen%2C+Shi-Shuai&rft.date=2021-01-01&rft.pub=Oxford+University+Press&rft.issn=0021-972X&rft.volume=106&rft.issue=1&rft.spage=120&rft_id=info:doi/10.1210%2Fclinem%2Fdgaa701&rft.externalDocID=A702242463
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon